July 13, 2017 08:00 AM EDT
People

Ex-GSK CEO An­drew Wit­ty goes biotech, tak­ing a board seat at G1

John Carroll

Editor & Founder

An­drew Wit­ty and G1 CEO Mark Vel­le­ca File Pho­to

An­drew Wit­ty may have just stepped out of the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Chi­na start­up in­jects CRISPR ther­a­py in­to the brain for the first time

Makary, in one of first com­ments on FDA pol­i­cy, floats new path­way for rare dis­ease drugs

Trodelvy and Keytru­da com­bo suc­ceeds in Phase 3 breast can­cer study

Roivant brings rare dis­ease pro­gram clos­er as Im­muno­vant CEO re­tires

FDA ap­proves Dupix­ent for hives, re­jects new Eylea dos­ing sched­ule

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times